ALK-Abelló’s GRAZAX Approved in Europe

ALK-Abelló A/S has completed the European Mutual Recognition Procedure for GRAZAX, the company's tablet-based vaccine against grass pollen allergy, and authorities in 27 European countries have now approved the tablet treatment.

GRAZAX is the first allergy tablet that improves patients' quality of life by treating the underlying cause of grass pollen allergy and not just the symptoms. Clinical studies show that GRAZAX has a good safety profile and provides significant efficacy within the first season of treatment. In a global evaluation of patients' perceptions of efficacy of GRAZAX treatment, 82 percent of the patients felt better or much better in the first season of treatment compared with the previous pollen seasons.

For patients, GRAZAX is an innovative and convenient treatment formulated as fast-dissolving once-a-day sublingual tablets that can be taken at home. This convenient formulation means that many more patients are expected to be offered the possibility of a medicine that treats the underlying cause of their allergy.

ALK-Abelló expects to launch GRAZAX on the first European markets by the end of 2006, ahead of the 2007 pollen season. The timing will vary from country to country.

For further information, please contact:

Jacob Frische,

Director, Communications Manager

Tel: +45 45 74 75 51

Email: jaf@dk.alk-abello.com

Or visit: www.alk-abello.com